Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib and Imatinib in Advanced Desmoid Tumor
NCT06219733Phase 2Withdrawn
- Sponsor
- MedPacto
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vactosertib in aggressive fibromatosis (AF), sponsored by MedPacto. Planned start Jun 2021; status: withdrawn.
02
Drugs
vactosertib
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on NCT06219733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06219733.